Clene Reports New CNM-Au8 Biomarker And Clinical Efficacy Data Submitted To FDA In Support Of Treatment For ALS
Portfolio Pulse from Benzinga Newsdesk
Clene Inc. (NASDAQ: CLNN) has submitted new biomarker and clinical efficacy data to the FDA for its CNM-Au8 treatment for ALS. The data shows significant clinical improvements in survival and functional status for treated participants, supporting a dual mechanism of action. This submission aims to guide an FDA Type C interaction for an accelerated approval pathway.
August 06, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clene Inc. has submitted new data to the FDA showing significant clinical improvements in ALS treatment with CNM-Au8. This could lead to an accelerated approval pathway, potentially boosting the stock price.
The submission of new data showing significant clinical improvements in ALS treatment could lead to an accelerated approval pathway by the FDA. This is likely to positively impact Clene Inc.'s stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100